In vivo studies with antisense oligonucleotides - PubMed (original) (raw)

TGF-β2 silencing to target biliary-derived liver diseases.

Dropmann A, Dooley S, Dewidar B, Hammad S, Dediulia T, Werle J, Hartwig V, Ghafoory S, Woelfl S, Korhonen H, Janicot M, Wosikowski K, Itzel T, Teufel A, Schuppan D, Stojanovic A, Cerwenka A, Nittka S, Piiper A, Gaiser T, Beraza N, Milkiewicz M, Milkiewicz P, Brain JG, Jones DEJ, Weiss TS, Zanger UM, Ebert M, Meindl-Beinker NM. Dropmann A, et al. Gut. 2020 Sep;69(9):1677-1690. doi: 10.1136/gutjnl-2019-319091. Epub 2020 Jan 28. Gut. 2020. PMID: 31992593 Free PMC article.